文献速递临床生化临床免疫质量管理与危急值

Lumipulse血浆p-tau217在专科临床神经化学实验室六个月的真实世界性能评估

Real-world performance of Lumipulse G plasma p-tau217: a six-month experience of a specialized clinical neurochemistry laboratory.
PubMed 文献 · Clin Chem Lab Med · 2026-04-29

该研究回顾性分析了Sahlgrenska大学医院2025年8月至2026年3月期间全部血浆p-tau217检测,以脑脊液Aβ42/40为参考标准评估一致性,并监测六个月分析性能。结果显示阳性符合率84.5%、阴性符合率87.5%,批内精密度良好但QC存在批次依赖性偏移,提示血浆p-tau217可作为AD临床评估的辅助工具。

要点

  • 血浆p-tau217与脑脊液Aβ42/40的阳性符合率84.5%,阴性符合率87.5%。
  • 批内精密度良好,CV低于7.3%;QC批次偏移经调查源于质控品而非检测性能。
  • 试剂批间一致性未见系统性差异,支持血浆p-tau217作为AD辅助诊断工具。

核心结论

  • Lumipulse血浆p-tau217在常规临床实践中表现出稳定的分析性能,并与脑脊液Aβ42/40保持良好一致性。

研究设计与样本

  • 回顾性评估Sahlgrenska大学医院临床神经化学实验室2025年8月至2026年3月全部血浆p-tau217检测,共1352次测量,其中121例有配对脑脊液Aβ42/40数据。

主要发现

  • 1352例血浆p-tau217检测中,541例(40.0%)为低概率、228例(16.9%)为中间概率、583例(43.1%)为高概率淀粉样病理。
  • 以脑脊液Aβ42/40为参考,血浆p-tau217阳性符合率84.5%(95%CI:72.6-92.7%),阴性符合率87.5%(95%CI:73.2-95.8%)。
  • 内部质控显示批内精密度良好,变异系数低于7.3%。
  • QC测量观察到批次依赖性偏移,最显著的一批为+14.4-18.4%,后续调查表明该偏差源于质控品而非检测性能。
  • 研究期间试剂批间一致性评估未发现系统性批号依赖效应。

关键数值与推荐

  • 血浆p-tau217预设临床截断值:<0.22 ng/L与>0.34 ng/L用于评估脑淀粉样蛋白阳性诊断准确性。

临床怎么用

  • 血浆p-tau217可作为阿尔茨海默病临床评估的辅助工具,支持治疗资格判定与监测。
  • 需持续进行质量控制监测,并对检测性能进行前瞻性评估。

局限性

  • 配对脑脊液Aβ42/40数据的样本量有限(121例)。
  • QC批次偏移来源于质控品,提示需关注质控品质量对性能评估的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Plasma p-tau217 is a leading blood-based biomarker for Alzheimer's disease (AD), offering high diagnostic accuracy and potential utility for treatment eligibility and monitoring. However, real-world data on concordance between cerebrospinal fluid (CSF) Aβ42/40 and plasma p-tau217 in routine clinical laboratory settings remain limited. METHODS: We retrospectively evaluated all plasma p-tau217 tests performed in the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital between August 2025 and March 2026. De-identified plasma p-tau217, additional blood biomarkers, and available CSF results were extracted from the laboratory information system. Concordance between plasma p-tau217 and CSF Aβ42/40 was evaluated by calculating positive and negative percent agreement, with CSF Aβ42/40 used as the reference standard. In addition, diagnostic accuracy for brain amyloid positivity was assessed using two predefined clinical cutoffs for plasma p-tau217 (<0.22 vs. >0.34 ng/L). Internal analytical performance was monitored over a six-month period using commercial quality control materials, with additional evaluation of lot-to-lot consistency for plasma p-tau217. RESULTS: Among 1,352 plasma p-tau217 measurements, paired CSF Aβ42/40 data were available for 121 individuals. Based on plasma p-tau217 probability categories, 541 samples (40.0 %) were classified as low probability, 228 (16.9 %) as intermediate probability, and 583 (43.1 %) as high probability for amyloid pathology. Using CSF Aβ42/40 as the reference standard, plasma p-tau217 demonstrated a positive percent agreement of 84.5 % (95 % CI: 72.6-92.7 %) and a negative percent agreement of 87.5 % (95 % CI: 73.2-95.8 %). Internal quality control analyses showed good within-batch precision, with coefficients of variation below 7.3 %. Batch-dependent bias was observed in QC measurements, most notably for one batch (+14.4-18.4 %); however, subsequent QC investigations indicated that this deviation originated from the QC material rather than from assay-related performance. Lot-to-lot consistency assessment did not reveal systematic reagent lot-dependent effects during the study period. CONCLUSIONS: Lumipulse plasma p-tau217 demonstrated stable analytical performance and consistent concordance with CSF Aβ42/40 in routine clinical practice. The observed agreement supports the feasibility of plasma p-tau217 as a supportive tool in the clinical evaluation of AD, while underscoring the need for continued quality control monitoring and prospective evaluation of assay performance.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Arslan B, Gobom J, Simrén J, et al. Real-world performance of Lumipulse G plasma p-tau217: a six-month experience of a specialized clinical neurochemistry laboratory. Clin Chem Lab Med. 2026. PMID: 42053135. doi:10.1515/cclm-2026-0370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。